Skip to main content
Premium Trial:

Request an Annual Quote

caBIG, Spotfire, Open Science Grid, Ariadne Genomics, GeneGo, Gene-IT

NCI’s caBIG Seeks Third-Party Service Providers
The National Cancer Institute’s Cancer Biomedical Informatics Grid program has issued a request for information “to gauge third-party interest in becoming a caBIG service provider,” according to a statement this week from Booz Allen Hamilton, caBIG’s primary contractor.
According to the RFI, the caBIG initiative is moving toward “self-sustainability,” which means that participants “will require support services to realize successful application of caBIG tools and products.”
Under the proposed service provider program, third-party organizations will provide user application support, informatics architecture and development support, code development services, and other services.
Service providers would be compensated directly by the organization that is benefiting from the support services, according to the RFI.
The RFI can be downloaded here. Responses are due Oct. 26.

GSK Deploys Spotfire’s DecisionSite Across Chemistry Team
Spotfire said this week that GlaxoSmithKline is using its DecisionSite software across its chemistry domain area.
In addition, Spotfire’s professional services team worked with GSK to develop custom analytic solutions.
Financial terms of the agreement were not disclosed.

NSF, DOE Award $30M to Open Science Grid
The National Science Foundation and the US Department of Energy have awarded a five-year, $30 million award to the Open Science Grid Consortium, OSG said this week.
The OSG includes computing resources from more than 50 sites in the United States, Asia, and South America that are shared through the OSG. These resources range from small clusters of 10 computers to large facilities with thousands of processors and millions of gigabytes of data storage.
Fifteen members of the OSG Consortium, including 11 US universities and four national laboratories, will receive funding through the NSF and DOE Office of Science awards.

NCI Purchases Site License for Ariadne’s Pathway Software
Ariadne Genomics said this week that the National Cancer Institute has purchased site licenses for its pathway analysis software, including its Pathway Studio desktop package and PathwayExpert enterprise software.
The NCI has also purchased a license to Ariadne’s ResNet database of more than 1 million interactions extracted from PubMed.
Financial terms of the agreement were not disclosed.

Germany’s Merck Expands License to GeneGo’s MetaCore
GeneGo said this week that Germany’s Merck has expanded its MetaCore license to provide access to all employees at the company for use in early discovery and compound safety testing.
"We see MetaCore as a further step into systems biology, a novel discipline which holds much promise for pharmaceutical research," said Friedrich Rippmann, director of bioinformatics and cheminformatics at Merck KGaA, in a statement.
Financial terms were not disclosed.

Biogen Idec to Use Gene-IT’s GenomeQuest for Patent Searching
Gene-IT said this week that Biogen Idec has agreed to use its GenomeQuest sequence search service as part of its patent searching process.
GenomeQuest combines sequence search and analytics with public and proprietary sequence content, including an indexed archive of more than 30 million patented sequences.
Financial terms of the agreement were not provided.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.